Literature DB >> 20615619

Evaluation of biologic effective dose and schedule of fractionation for preoperative radiotherapy for rectal cancer: meta-analyses and meta-regression.

Gustavo Arruda Viani1, Eduardo Jose Stefano, Francisco Vendito Soares, Sergio Luis Afonso.   

Abstract

PURPOSE: To evaluate whether the risk of local recurrence depends on the biologic effective dose (BED) or fractionation dose in patients with resectable rectal cancer undergoing preoperative radiotherapy (RT) compared with surgery alone. METHODS AND MATERIALS: A meta-analysis of randomized controlled trials (RCTs) was performed. The MEDLINE, Embase, CancerLit, and Cochrane Library databases were systematically searched for evidence. To evaluate the dose-response relationship, we conducted a meta-regression analysis. Four subgroups were created: Group 1, RCTs with a BED >30 Gy(10) and a short RT schedule; Group 2, RCTs with BED >30 Gy(10) and a long RT schedule; Group 3, RCTs with BED ≤ 30 Gy(10) and a short RT schedule; and Group 4, RCTs with BED ≤ 30 Gy(10) and a long RT schedule.
RESULTS: Our review identified 21 RCTs, yielding 9,097 patients. The pooled results from these 21 randomized trials of preoperative RT showed a significant reduction in mortality for groups 1 (p = .004) and 2 (p = .03). For local recurrence, the results were also significant in groups 1 (p = .00001) and 2 (p = .00001).The only subgroup that showed a greater sphincter preservation (SP) rate than surgery was group 2 (p = .03). The dose-response curve was linear (p = .006), and RT decreased the risk of local recurrence by about 1.7% for each Gy(10) of BED.
CONCLUSION: Our data have shown that RT with a BED of >30 Gy(10) is more efficient in reducing local recurrence and mortality rates than a BED of ≤ 30 Gy(10), independent of the schedule of fractionation used. A long RT schedule with a BED of >30 Gy(10) should be recommended for sphincter preservation.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20615619     DOI: 10.1016/j.ijrobp.2010.03.008

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  10 in total

1.  Induction FOLFOX followed by preoperative hyperfractionated radiotherapy plus bolus 5-fluorouracil in locally advanced rectal carcinoma: single arm phase I-II study.

Authors:  Engy M Aboelnaga; Mohamed A Daoud; Entesar I Eladl; Amir M Zaid
Journal:  Med Oncol       Date:  2015-03-07       Impact factor: 3.064

2.  Feasibility of relatively low neoadjuvant radiation doses for locally advanced rectal cancer: A propensity score-matched analysis.

Authors:  Wenyuan Ye; Liming Shi; Liwen Qian; Yikan Sun; Xiaonan Sun
Journal:  Cancer Rep (Hoboken)       Date:  2019-06-02

3.  Long-term results of a randomized trial in locally advanced rectal cancer: no benefit from adding a brachytherapy boost.

Authors:  Ane L Appelt; Ivan R Vogelius; John Pløen; Søren R Rafaelsen; Jan Lindebjerg; Birgitte M Havelund; Søren M Bentzen; Anders Jakobsen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-08       Impact factor: 7.038

4.  The timing of surgery after preoperative short-course S-1 chemoradiotherapy with delayed surgery for T3 lower rectal cancer.

Authors:  Naohito Beppu; Nagahide Matsubara; Masashi Noda; Tomoki Yamano; Hiroshi Doi; Norihiko Kamikonya; Naoki Yamanaka; Hidenori Yanagi; Naohiro Tomita
Journal:  Int J Colorectal Dis       Date:  2014-08-28       Impact factor: 2.571

5.  Progress in rectal cancer treatment.

Authors:  Wim P Ceelen
Journal:  ISRN Gastroenterol       Date:  2012-08-30

6.  Neoadjuvant short-course hyperfractionated accelerated radiotherapy (SC-HART) combined with S-1 for locally advanced rectal cancer.

Authors:  Hiroshi Doi; Naohito Beppu; Soichi Odawara; Masao Tanooka; Yasuhiro Takada; Yasue Niwa; Masayuki Fujiwara; Fumihiko Kimura; Hidenori Yanagi; Naoki Yamanaka; Norihiko Kamikonya; Shozo Hirota
Journal:  J Radiat Res       Date:  2013-05-08       Impact factor: 2.724

7.  Preoperative chemoradiation for locally advanced rectal cancer: comparison of three radiation dose and fractionation schedules.

Authors:  Shin-Hyung Park; Jae-Chul Kim
Journal:  Radiat Oncol J       Date:  2016-06-17

8.  High Biologically Effective Dose Radiotherapy for Brain Metastases May Improve Survival and Decrease Risk for Local Relapse Among Patients With Small-Cell Lung Cancer: A Propensity-Matching Analysis.

Authors:  Qing-Yang Zhuang; Jin-Luan Li; Fei-Fei Lin; Xi-Jin Lin; Huaqin -Lin; Youjia -Wang; Yaobin -Lin; Yun-Xia Huang; Xue-Qing Zhang; Li-Rui Tang; Jun-Xin Wu
Journal:  Cancer Control       Date:  2020 Apr-Jun       Impact factor: 3.302

9.  Preoperative radiotherapy and curative surgery for the management of localised rectal carcinoma.

Authors:  Iosief Abraha; Cynthia Aristei; Isabella Palumbo; Marco Lupattelli; Stefano Trastulli; Roberto Cirocchi; Rita De Florio; Vincenzo Valentini
Journal:  Cochrane Database Syst Rev       Date:  2018-10-03

10.  Phase II study on early start of chemotherapy after excising primary colorectal cancer with distant metastases (Pearl Star 02).

Authors:  Yoichiro Yoshida; Naoya Aisu; Daibo Kojima; Toshiyuki Mera; Fumiaki Kiyomi; Yuichi Yamashita; Suguru Hasegawa
Journal:  Ann Gastroenterol Surg       Date:  2017-08-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.